Watson Faces Suits Over Trilipix, Rapamune ANDAs
Watson Pharmaceuticals Inc. has been hit with two patent infringement suits over abbreviated new drug applications to introduce generic versions of Abbott Laboratories cholesterol treatment Trilipix and Pfizer Inc. organ rejection...To view the full article, register now.
Already a subscriber? Click here to view full article